Rankings
▼
Calendar
KYMR Q4 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KYMR
Kymera Therapeutics, Inc.
$7B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$3M
-61.3% YoY
Gross Profit
$79M
2763.6% margin
Operating Income
-$98M
-3422.9% margin
Net Income
-$87M
-3043.0% margin
EPS (Diluted)
$-0.98
QoQ Revenue Growth
+3.5%
Cash Flow
Operating Cash Flow
-$67M
Free Cash Flow
-$67M
Stock-Based Comp.
$14M
Balance Sheet
Total Assets
$1.7B
Total Liabilities
$163M
Stockholders' Equity
$1.6B
Cash & Equivalents
$357M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3M
$7M
-61.3%
Gross Profit
$79M
$7M
+968.9%
Operating Income
-$98M
-$81M
-21.2%
Net Income
-$87M
-$71M
-23.0%
← FY 2025
All Quarters